We previously observed such an engagement of the complement system following treatment of the same tumor model with NBTXR3+XRT in tandem with checkpoint inhibitors of PD1, LAG3, and TIGIT — a treatment combination that yielded similarly impressive results to the therapy in this study (23). This evidence concerns the gene PDCD1 and neoplasm.